# PETS earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/PETS) · [Earnings tab](https://www.lopjlb.com/stock/PETS?tab=earnings)

Updated: 2026-07-27T03:55:10

Quarters analyzed: 8

## Cross-quarter narrative

PetMed Express transitioned from acquisition-fueled growth (PetCareRx, +11.5% YoY in FQ1'24) to a multi-year restructuring. Early quarters highlighted new customer gains (+25% YoY) and recurring revenue rising to 51%, but core returning customers declined persistently. Dividend suspension in FQ2'24 funded tech (OMS, AutoShip Gen2, CRM), food expansion (Purina, Hill's, Royal Canin), VetLive, and insurance (Pumpkin). A sales tax restatement (FQ3'24) and new CEO Sandra Campos' 4-pillar plan (FQ4'24) marked a reset. FY2025 saw sales decline 13-16% per quarter amid macro pressure on price-sensitive owners, technology disruptions, and intentional marketing cuts. Gross margin improved to 32.6% by FY2026 Q4 aided by a NY tax settlement; $6.1M annualized cost savings from vendor exits and tech modernization were delivered. The Board rejected two unsolicited offers ($4-4.25/share) to remain independent. Demand shows early sequential stabilization (prescriptions, food, AutoShip) but full-year sales down 21.1%; adjusted EBITDA loss $15.4M vs prior $0.7M profit. Focus shifted to B2B partnerships (Rural King) and organic operational improvements with $21.4M cash, no debt.

## Latest CallCard · Q4

PetMed Express reports pivotal year with slowing revenue decline (Q4 -15.6%), sequential Q4 growth, regulatory compliance restored, $6.1M annualized cost savings, tech stack modernized, and Board rejects $4-4.25/share acquisition offers to remain independent. No debt, $21.4M cash. Full-year sales do

**Guidance:** vague — No specific revenue, earnings, or cash flow guidance given for FY2027; management only outlines strategic priorities (operational excellence, B2B expansion, website optimization).

**Tone:** mgmt 0.3 · Q&A pressure 0 · divergence 0.3

Management highlights 'substantial progress,' 'green shoots,' 'positive momentum,' and confidence in foundation for long-term value creation, while acknowledging full-year challenges and nonrecurring charges.

### Demand visibility

Sequential Q4 improvement and green shoots in prescriptions, food, autoship suggest early stabilization, but full-year down 21.1% and visibility remains limited.

Q4 net sales down 15.6% YoY but up sequentially from Q3, driven by prescription medication and autoship sales. Management cites 'green shoots in the second half of the year in important areas like prescription medication sales, prescription and nonprescription food sales and autoship sign-ups.' However, full-year prescription medication sales decline remains primary driver of 21.1% revenue drop.

### Margins / costs

Gross margin improved 270 bps to 32.6% aided by NY tax settlement; G&A down 8.6% YoY from cost optimization; $6.1M annualized savings from vendor exits; advertising up due to vendor co-op funds; D&A up from tech investments.

Q4 gross profit 32.6% vs 29.9% prior year, primarily driven by $2.8M benefit from NY sales tax liability settlement. G&A $11.4M vs $12.5M (8.6% decrease) from cost optimization. Advertising $5.8M vs $5.4M increase due to presentation of co-op funds from vendors. D&A $2.4M vs $2.1M reflecting continued tech infrastructure investments. Full-year adjusted EBITDA loss $15.4M vs positive $0.7M prior year.

### Capital allocation

No debt, $21.4M cash; Board rejected two unsolicited acquisition offers ($4-4.25/share) to remain independent; focus on organic operational improvements, technology, and B2B partnerships; no dividends, buybacks, or acquisitions mentioned.

Balance sheet shows $21.4M cash and zero debt as of March 31, 2026. Board evaluated two nonbinding proposals at $4-4.25/share, solicited other interest, but determined best interest to continue as independent public company. Capital directed to ERP, fraud prevention, call center tech, and vendor relationship optimization yielding $6.1M annualized savings.

### Milestones

- **Regulatory compliance restoration** [delivered]: Filed FY2025 10-K in Oct 2025, completed Q1/Q2 FY2026 filings in Dec 2025, changed auditor to Baker Tilly, held Annual Shareholder Meeting Jan 2026.
- **Internal controls remediation** [delivered]: Fully remediated 3 previously disclosed material weaknesses: tone at the top, complex accounting issues, income taxes.
- **Cost reduction via vendor exits** [delivered]: Exited underperforming vendor relationships in H2 FY2026 yielding ~$6.1M annualized savings.
- **Operational reorganization** [delivered]: Strategically reorganized pharmacy, call center, distribution centers to optimize headcount productivity, improving operational performance and customer experience.
- **Technology stack modernization** [delivered]: Successfully implemented new ERP system, fraud prevention system, and call center technology (phone system backbone).
- **Leadership restructuring** [delivered]: Created Chief Growth Officer role aligning marketing, buying, merchandising, site merchandising; internal promotions across distribution, customer care, pharmacy operations.
- **Employee benefits expansion & culture** [delivered]: Meaningfully expanded employee benefits; employee satisfaction ratings substantially increased; recognized 40+ tenured employees at 30th anniversary.
- **B2B partnership - Rural King MSA** [new]: Recently announced Master Services Agreement with Rural King for white label pharmacy fulfillment services to expand market footprint.

### Fears / risks

- **Revenue decline persistence**: Full-year net sales down 21.1% YoY; Q4 still down 15.6% despite sequential improvement; prescription medication sales remain primary drag.
- **Profitability pressure**: Full-year adjusted EBITDA loss $15.4M vs positive $0.7M prior year; net loss $57.3M including $26.7M goodwill impairment; reliance on one-time tax settlement for margin improvement.
- **Execution risk on B2B partnerships**: New Master Services Agreement with Rural King and other white-label fulfillment services are early-stage; success depends on partner integration and demand.
- **Competitive and market dynamics**: No discussion of competitive landscape, online pharmacy competition, or pet medication market trends; visibility into demand drivers limited.
- **Shareholder activism / M&A overhang**: Two unsolicited offers rejected at $4-4.25/share; Board remains open to future proposals, creating potential distraction or valuation uncertainty.
- **Technology implementation risk**: Major ERP, fraud prevention, and call center systems recently implemented; ongoing optimization and user experience improvements needed; operational risk if issues arise.
- **Regulatory and compliance history**: Prior material weaknesses and delayed filings (10-K filed Oct 2025 for FY2025) indicate historical control deficiencies; though remediated, recurrence risk exists.
- **Key person / leadership transition risk**: Interim CEO/President and Interim CFO roles; leadership reorganization recent; long-term permanent leadership not confirmed.

### Key quotes

> “Fiscal year 2026 was a pivotal year for PetMed Express, during which we made significant financial, operational and cultural improvements that are aimed to put the company back on track for sustainable long-term results.”

> “We were pleased to deliver a sequential quarterly increase in fourth quarter net sales, our first Q4 sequential quarterly increase since fiscal year 2024, demonstrating some positive momentum.”

> “Gross profit this year was 32.6% compared to 29.9% in the prior year, a 270 basis point improvement. This improvement was primarily driven by the impact of our settlement of the New York sales tax liability.”

> “The Board determined that it is in the best interest of the company and its stockholders not to proceed with either of the publicly announced proposals and consequently, PetMeds is continuing to operate as an independent publicly traded”

## Quarter one-liners

- **2026 Q4:** PetMed Express reports pivotal year with slowing revenue decline (Q4 -15.6%), sequential Q4 growth, regulatory compliance restored, $6.1M annualized cost savings, tech stack modernized, and Board rejects $4-4.25/share acquisition offers to remain independent. No debt, $21.4M cash. Full-year sales do
- **2025 Q3:** PetMed reported a modest Q3 EBITDA boost and cost savings while highlighting a digital overhaul, marketing reset and ongoing demand pressure on price‑sensitive pet owners.
- **2025 Q2:** PETS Q2 sales fell 16% to $60M on consumer pressure and intentional marketing cuts; gross margin rose 80bps YoY to 29.1%; adj EBITDA $2.1M; new CFO onboard; consolidation complete; marketing ramp planned for H2.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights positive developments: g
- **2025 Q1:** PetMed Q1 2025 sales fell 13% with margin down 230 bps, but early cost‑saving, tech upgrades and new leadership show improving inventory, digital metrics and $5 M annualized savings.
- **2024 Q4:** New CEO Sandra Campos outlines 4-pillar transformation (brand consolidation, cash flow, retention, tech/AI) after PetCareRx acquisition; Q4 sales +6.6% but EBITDA down sharply on integration costs; $55M cash, no debt.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Prepared remarks emphasize growth opport
- **2024 Q3:** PetMed Express reports Q3 sales up 11% YoY to $65.3M but announces multi-period restatement due to sales tax accounting errors and deferred tax asset misstatement, delaying 10-Q filing; AutoShip & Save now 52% of revenue, Hill's Science Diet partnership added.','tone': {'mgmt': 0.2, 'mgmt_rationale'
- **2024 Q2:** PetMed Express Q2 sales rose 9% YoY to $71M driven by PetCareRx acquisition; recurring revenue reached 51% of sales; core returning customers still declining single-digit; dividend suspended to fund tech upgrades, food expansion, VetLive, and insurance. Net loss $70K, Adj EBITDA $3.2M vs $7.1M prior
- **2024 Q1:** PetMed Express reports 11.5% YoY revenue growth to $78.2M in FQ1'24 driven by PetCareRx acquisition; new customers up 25% YoY, reorder sales up 7%; launching pet insurance with Pumpkin, expanding telemedicine to new states; targeting PetCareRx EBITDA accretion by fiscal year-end. Dividend under revi

## Theme arcs

- **PetCareRx integration** (improving): Moved from on-track acquisition integration (FQ1'24) to delivered (FQ2'24) to realized cost savings on-track (FQ3'25) and completed via vendor exits and tech consolidation (FY2026 Q4).
- **Core customer retention** (deteriorating): Returning customer base declined single-digit from FQ1'24 through FQ2'25; stabilization not achieved despite AutoShip growth to 52% of revenue.
- **New customer acquisition** (stable): Consistently strong at ~25% YoY growth (FQ1'24, FQ2'24) but later quarters note conversion challenges despite traffic gains (FQ3'25).
- **Technology modernization** (improving): Progressed from OMS upgrade and AutoShip Gen2 on-track (FQ2'24) to call center modernization, website refresh, mobile app, BNPL, AI workforce tool delivered (FQ1'25-FQ3'25) to full stack modernization delivered (FY2026 Q4).
- **Product diversification (food, insurance, telehealth)** (improving): Purina delivered FQ1'24; Royal Canin, Hill's, insurance, VetLive delivered FQ2'24; PetHealthMD.com, BNPL added FQ3'25; food cross-sell awareness campaigns started FQ2'24.
- **Profitability and cost structure** (deteriorating): Adj EBITDA fell 55% YoY to $3.2M (FQ2'24); full-year adjusted EBITDA loss $15.4M (FY2026) vs $0.7M profit prior; gross margin improved to 32.6% (FY2026 Q4) aided by one-time tax settlement.
- **Capital allocation and balance sheet** (stable): Dividend suspended FQ2'24; no dividends/buybacks since; cash $55M (FQ4'24) to $21.4M (FY2026 Q4); no debt throughout; reinvestment in growth initiatives consistent.
- **Leadership and governance** (new): New CEO (FQ4'24), new CFO (FQ2'25), executive hires (FQ1'25), leadership restructuring delivered (FY2026 Q4); Board rejected acquisition offers (FY2026 Q4).
- **Regulatory and compliance** (resolved): Sales tax restatement and deferred tax asset misstatement (FQ3'24) led to compliance restoration and internal controls remediation delivered (FY2026 Q4).
- **B2B partnership execution** (new): Master Services Agreement with Rural King and white-label fulfillment early-stage (FY2026 Q4); wholesale inventory initiative failed with $2.1M write-down (FY2026 Q3).

## Guidance path

2024 Q1:vague → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2026 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/PETS`